Pukanatide API

Name	Pukanatide
Chinese name	普卡那肽
Cas Number	467426-54-6
Source	India
Qualifications	USDMF/-/-/-/-

Pukanatide was originally developed by Callisto Pharmaceuticals in the United States and transferred to Synergy Pharmaceuticals for development. It was approved by the U.S. Food and Drug Administration (FDA) on January 19, 2017. Pukanatide is an analog of uroguanylin (uroguanylin). It contains a 16 amino acid cyclic polypeptide. It acts as a natriuretic guanylate cyclase receptor agonist and can regulate the gastrointestinal tract. Acid-base ions induce fluid transport into the gastrointestinal tract and increase gastrointestinal motility. The adverse reaction of prakanatide is lower than that of linaclotide. In clinical trials, the rate of removal due to severe diarrhea is much lower than that of linaclotide. In a clinical trial for the treatment of CIC, the rate of pukanatide diarrhea<6%, and linaclotide 16%. The domestic prevalence of digestive diseases is much higher than that in Europe and the United States, and the domestic prevalence of the indications targeted by pukanatide is higher than that in European and American countries. Therefore, the future market potential of pukanatide is greater. According to Thomson Reuters forecasts, pukanatide will reach $400 million in sales in 2020.

Hot Tags: pukanatide api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Bemeprost API, Letrozole API, Escitalopram Oxalate API, Cinacalcet Hydrochloride API, Tetrabenazine API, Temozolomide API

• Previous: Eperisone Hydrochloride API
• Next: Micuronium Chloride API